Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

This study has been terminated.
(See Detailed Description)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01155063
First received: June 28, 2010
Last updated: September 25, 2012
Last verified: September 2012
Results First Received: August 17, 2012  
Study Type: Observational
Study Design: Observational Model: Case Control;   Time Perspective: Prospective
Condition: Early Breast Cancer
Intervention: Other: Aromasin (exemestane)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Exemestane Participants with 2-3 years of initial adjuvant tamoxifen therapy who received exemestane (Aromasin) 25 milligram (mg) oral tablet once daily to complete 5 years of adjuvant hormonal therapy.

Participant Flow:   Overall Study
    Exemestane
STARTED   89 
COMPLETED   0 
NOT COMPLETED   89 
Adverse Event                1 
Withdrawal by Subject                1 
Study terminated by sponsor                87 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Exemestane Participants with 2-3 years of initial adjuvant tamoxifen therapy who received exemestane (Aromasin) 25 mg oral tablet once daily to complete 5 years of adjuvant hormonal therapy.

Baseline Measures
   Exemestane 
Overall Participants Analyzed 
[Units: Participants]
 89 
Age 
[Units: Years]
Mean (Standard Deviation)
 59.2  (7.3) 
Gender 
[Units: Participants]
 
Female   89 
Male   0 
Type of Tumor [1] 
[Units: Participants]
 
Ductal carcinoma   5 
Lobular carcinoma   6 
Invasive ductal carcinoma   50 
Invasive lobular carcinoma   20 
Papillary carcinoma   0 
Medullary carcinoma   5 
Mucinous (colloid) carcinoma   2 
Other   1 
[1] Number of participants with different types of tumor such as; ductal carcinoma, lobular carcinoma, invasive ductal carcinoma, invasive lobular carcinoma, papillary carcinoma, medullary carcinoma, mucinous (colloid) carcinoma and others.
Type of Surgery [1] [2] 
[Units: Participants]
 NA [2] 
[1] Number of participants who had undergone different type of surgeries which included mammectomy, radical resection, radical mastectomy, mastectomy, mammectomy with lymphadenectomy, ovariectomy, mammectomy with lymph node dissection, mastectomy type madden of mammary gland.
[2] Data for this pre-specified outcome measure was collected and reported in individual participant listings but not statistically summarized for analysis.
Hormone Receptor Status [1] 
[Units: Participants]
 
Estrogen receptor: Positive   87 
Estrogen receptor: Negative   1 
Estrogen receptor: Unknown   1 
Progesterone receptor: Positive   84 
Progesterone receptor: Negative   4 
Progesterone receptor: Unknown   1 
[1] Number of participants with positive or negative estrogen and progesterone receptors.
Lymph Node Status [1] 
[Units: Participants]
 NA [1] 
[1] Data for this pre-specified outcome measure was collected and reported in individual participant listings but not statistically summarized for analysis.
Tumor Node Metastasis (TNM) Stage [1] 
[Units: Participants]
 
Stage I   20 
Stage IIA   42 
Stage IIB   13 
Stage IIIB   8 
Stage IV   0 
Stage IIIA   4 
Stage IIIC   2 
[1] TNM was based on size of tumor, if cancer cells had spread to nearby lymph nodes (LN), or distant (to other parts of the body) metastasis had occurred. Stages included: stage 0(no evidence of cancer cells), stage 1(T1N0M0), stage IIA(T0N1M0, T1N1M0, T2N0M0), stage IIB(T2N1M0, T3N0M0), stage IIIA(T0N2M0, T1N2M0, T2N3M0, T3N1orN2M0), stage IIIC(any TN3M0), stage IV(anyT anyNM1), where T0=early form of tumor, T1= <2 centimeter(cm), T2=2-5 cm, T3= >2 cm, T4=large sized tumor, N0=not spread to LN, N1=spread to 1 to 3,N2=spread to 4 to 9,N3=spread >10 axillary LN, M0=no metastasis, M1= Metastasis.
Histopathological Grade [1] 
[Units: Participants]
 
Grade 1   16 
Grade 2   43 
Grade 3   5 
Grade 4   0 
Unknown   25 
[1] The grade of a cancer depends on what the cells look like and the growth-rate. Lower grade indicates a slower-growing cancer and a higher grade indicates a faster-growing one. Grade 1 (resemble normal cells, not growing rapidly), grade 2 (grow faster than normal cells), grade 3 and 4 (abnormal cells, grow and spread aggressively).
Number of participants on chemotherapy [1] [2] 
[Units: Participants]
 NA [2] 
[1] Number of participants who received chemotherapy. Chemotherapeutic drugs included cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel, epirubicin, fluorouracil.
[2] Data for this pre-specified outcome measure was collected and reported in individual participant listings but not statistically summarized for analysis.
Number of participants on radiotherapy [1] [2] 
[Units: Participants]
 NA [2] 
[1] Number of participants who received radiotherapy as measured in radiations per centigray (Rads/cGy).
[2] Data for this pre-specified outcome measure was collected and reported in individual participant listings but not statistically summarized for analysis.
Concomitant morbidities in the past [1] 
[Units: Participants]
 
Myocardial infarction   2 
Thyroid disorder   1 
Cholecystitis   1 
Drug hypersensitivity   1 
Lipid metabolism disorder   1 
Rheumatic fever   1 
Neoplasm malignant   1 
Rectal cancer   1 
Reproductive tract disorder   19 
Hypertension   2 
[1] Participants who had a concomitant morbidity in the past; participants with more than one concomitant co-morbidity were counted for each of the co-morbidity classes applicable.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Adverse Events (AEs)   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

2.  Secondary:   Number of Participants With Concomitant Morbidities   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

3.  Secondary:   Number of Participants With Concomitant Medications   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

4.  Secondary:   Percentage of Participants Who Discontinued the Study Medication   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

5.  Secondary:   Number of Participants With Reasons for Discontinuation From Study Treatment   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

6.  Secondary:   Time to Discontinuation of Study Medication   [ Time Frame: Month 0 up to Month 36 or early withdrawal ]

7.  Secondary:   Percentage of Participants With Recurrent Disease   [ Time Frame: Month 36 or early withdrawal ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was prematurely discontinued, therefore not all data was analyzed and only one outcome measure timeframe was presented.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com



Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01155063     History of Changes
Other Study ID Numbers: A5991092
Study First Received: June 28, 2010
Results First Received: August 17, 2012
Last Updated: September 25, 2012
Health Authority: Russia: Central Ethic Committee